As of November 14, 2026, the federal rule that lets clinicians prescribe ADHD stimulants by telehealth without ever seeing you in person ends at the end of the day on December 31, 2026. No extension or replacement rule has been published. If nothing is published by then, starting January 1, 2027 a prescriber who has never examined you in person generally could not prescribe a controlled ADHD medication by telehealth. Under federal law, patients who have had at least one in-person visit with their prescriber, and people on non-controlled medications such as Strattera, are not affected.
Educational information, not medical or legal advice. Don’t start, stop or change a medication without your prescriber. No pharmaceutical sponsorship and no affiliate links.
What changes on January 1, 2027, by medication
This table assumes the worst case: December 31 passes with no new extension and no final rule. Status checked in the Federal Register on November 14, 2026.
| Your medication | Federal schedule | Through December 31, 2026 | From January 1, 2027 if nothing replaces the rule |
|---|---|---|---|
| Adderall, Vyvanse, Ritalin, Concerta, Focalin and other stimulants | Schedule II | Can be prescribed by telehealth with no in-person visit. | Your prescriber must have examined you in person at least once. After one in-person evaluation, they can keep prescribing by telehealth. |
| Simtriyo (centanafadine) | Schedule III since October 30, 2026 | Can be prescribed by telehealth with no in-person visit. | Same in-person requirement as the stimulants. |
| Strattera (atomoxetine), Qelbree (viloxazine), guanfacine ER, clonidine ER | Not controlled | No federal in-person requirement. | No change. |
The in-person rule comes from the Ryan Haight Act of 2008. In the DEA’s words, once a practitioner “has conducted at least one in-person medical evaluation of a particular patient,” the Act’s limits on remote prescribing “no longer apply to that specific practitioner-patient relationship.” So one in-person visit with the clinician who prescribes for you is the step that protects your prescription whatever the DEA does.
Where the replacement rule stands. The DEA sent a final version of its telemedicine “special registration” rule to the White House regulatory office (OIRA) on August 25, 2026. On November 14, 2026 the federal tracker still listed it as pending review, and its text is not public. A rule is not in force until it is published in the Federal Register.
This page reflects federal rules as of November 14, 2026. We check the Federal Register for a new extension or a final rule and update this page when one is published.
What are the current DEA telehealth rules for ADHD medication?
Most ADHD stimulants, including amphetamine (Adderall), lisdexamfetamine (Vyvanse), and methylphenidate (Ritalin, Concerta), are Schedule II controlled substances. A 2008 federal law, the Ryan Haight Act, generally requires an in-person medical evaluation before a controlled substance is prescribed over the internet, with limited exceptions.
During the COVID-19 public health emergency, the DEA and HHS relaxed that requirement. Since then they have extended the relaxation several times. The current version is the Fourth Temporary Extension, published in the Federal Register on December 31, 2025 and effective January 1 through December 31, 2026.
Under it, a DEA-registered practitioner may prescribe Schedule II–V controlled substances by telemedicine to a patient they have never evaluated in person, as long as:
- the prescription is for a legitimate medical purpose, issued in the usual course of professional practice;
- the visit uses an interactive telecommunications system meeting the federal definition the rule cites;
- the practitioner is authorized under their DEA registration (or exempt from registration); and
- the prescription meets all other federal prescription requirements.
The rule states that the authorization is "in effect until the end of the day December 31, 2026." Its stated purpose is to prevent a "telemedicine cliff" while the DEA finishes permanent regulations.
What happens after December 31, 2026?
There are three realistic paths. As of November 14, 2026, none has been published.
| Scenario | What it would mean for telehealth ADHD prescriptions |
|---|---|
| Another temporary extension | Current flexibilities continue for a set period. The 2026 rule is already the fourth temporary extension, and another is not guaranteed. |
| A final "special registration" rule | Telehealth prescribing of controlled substances without an in-person visit continues, but only for clinicians who hold the new registration and follow its extra prescription, recordkeeping, and reporting requirements. Details depend on the final text. |
| The flexibilities lapse with nothing replacing them | The general Ryan Haight Act in-person evaluation requirement returns. A clinician who has never examined you in person would generally be unable to prescribe a new controlled-substance prescription by telehealth unless a statutory exception applies. |
About the special registration rule: in January 2025 the DEA proposed a "Special Registrations for Telemedicine and Limited State Telemedicine Registrations" rule. It would create three types of special registration and add heightened prescription, recordkeeping, and reporting requirements. The comment period closed in March 2025. A final version went to OIRA for review on August 25, 2026. As of November 14, 2026, it had not been published in the Federal Register, so its final requirements are unknown.
What this does not affect: non-controlled ADHD medications. Atomoxetine (Strattera), viloxazine (Qelbree), clonidine ER, and guanfacine ER are not controlled substances, so these DEA rules do not apply to them. State telehealth and licensing rules still do.
Newer controlled options are affected. Centanafadine (Simtriyo) was placed in Schedule III effective October 30, 2026. The current flexibilities cover Schedules II–V, so telehealth prescribing of it would be affected by the same deadline.
What should patients do now?
- Ask your prescriber directly: "If the telehealth flexibilities end on December 31, can you keep prescribing my medication? Do you need to see me in person first?" Many clinicians are already planning for this.
- If you have never had an in-person visit with your current prescriber, consider scheduling one before the end of the year, or ask whether they can arrange one with a colleague. Ask how they would handle an in-person evaluation under whichever rule applies.
- Do not stockpile or try to fill early. Controlled-substance prescriptions are tightly regulated, and attempting early fills can create problems with your pharmacy and your prescriber.
- Have a backup plan. Know whether your primary care clinician would be willing to take over prescribing if your telehealth prescriber cannot continue.
- Do not stop suddenly without guidance. A gap in medication can bring symptoms back quickly, and some non-stimulants, like guanfacine, must be tapered rather than stopped. If access is interrupted, talk to a clinician about a safe plan.
- Watch for a DEA announcement. Any new extension or final rule will be published in the Federal Register; we will update this page when it is.
What about state rules?
Federal DEA rules are only one layer. States set their own requirements for telehealth, prescriber licensing, and controlled-substance prescribing, and some are stricter than federal law. Some states have their own in-person or prescribing requirements for controlled substances that apply regardless of the federal flexibilities, and clinicians generally need to be licensed in the state where you are located during the visit. Ask your prescriber or your state medical or pharmacy board what applies to you.
How do you spot an unsafe ADHD telehealth service?
Most telehealth ADHD care is legitimate. But the risks are not hypothetical. In November 2025, a federal jury convicted the founder/CEO and the clinical president of Done, a digital health company, of conspiracy to distribute controlled substances and conspiracy to commit health care fraud. According to the Justice Department, evidence at trial showed a roughly $100 million scheme in which Done provided easy access to about 40 million pills of Adderall and other stimulants, with initial appointments capped at less than half the length of a typical psychiatric evaluation and an "auto-refill" process that kept prescriptions going with little clinical contact.
Warning signs worth taking seriously:
- The ads or website promise a prescription, or a specific drug, before any evaluation.
- The evaluation is a short questionnaire plus a brief call, with no history, no rating scales, and no questions about other conditions such as anxiety, depression, sleep, or substance use.
- No one asks about your heart health, blood pressure, or family cardiac history before starting a stimulant.
- Refills continue automatically with no follow-up visits to check how the medication is working and what side effects you have.
- You cannot find the prescriber's name, credentials, or state license, or you cannot reach a clinician when something goes wrong.
A good evaluation, in person or by video, looks like the one described in our ADHD diagnosis process guide and our diagnosis guide. For cost expectations, see how much an ADHD diagnosis costs.
If you have chest pain, fainting, a severe reaction, or thoughts of harming yourself while on any ADHD medication, call 911 or go to the nearest emergency department. In the US you can also call or text 988.
Frequently asked questions
Can I still get Adderall through telehealth in 2026?
Yes, through December 31, 2026. The DEA and HHS Fourth Temporary Extension lets DEA-registered clinicians prescribe Schedule II–V medications by telemedicine without a prior in-person visit, if the rule’s conditions and your state’s laws are met.
When do the DEA telehealth flexibilities expire?
The current authorization is in effect until the end of the day on December 31, 2026, unless the DEA extends it or replaces it with a final rule.
Will I need an in-person visit for ADHD medication in 2027?
It depends on what the DEA does before the deadline. If the flexibilities lapse with no replacement, the federal in-person evaluation requirement for prescribing controlled substances would generally return. Ask your prescriber now about their plan.
Do the DEA telehealth rules apply to non-stimulant ADHD medications?
No. Atomoxetine, viloxazine, clonidine ER, and guanfacine ER are not controlled substances, so DEA telemedicine rules do not apply to them. State telehealth rules still apply.
What is the DEA special registration for telemedicine?
It is a framework the DEA proposed in January 2025 that would create special registrations for clinicians who prescribe controlled substances by telemedicine, with extra prescribing, recordkeeping, and reporting requirements. A final version has been under White House review since August 25, 2026. As of November 14, 2026, it had not been published.
References
- DEA and HHS (2025). Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications. Federal Register, December 31, 2025 (90 FR 61301, Doc. 2025-24123).
- DEA (2025). Special Registrations for Telemedicine and Limited State Telemedicine Registrations. Proposed rule, Federal Register, January 17, 2025 (Doc. 2025-01099).
- DEA (2026). Schedules of Controlled Substances: Placement of Centanafadine in Schedule III. Interim final rule, Federal Register, October 30, 2026 (91 FR 68470).
- Office of Information and Regulatory Affairs. Pending EO 12866 regulatory review, RIN 1117-AB40: Special Registrations for Telemedicine and Limited State Telemedicine Registrations, final rule stage, received August 25, 2026. Read November 14, 2026.
- US Department of Justice (2025). Founder/CEO and clinical president of digital health company convicted in $100M Adderall distribution and health care fraud scheme. Press release, November 19, 2025.